

**Notice of References Cited**

Application/Control No.

10/763,424

Applicant(s)/Patent Under

Reexamination

KARLIK ET AL.

Examiner

Maher M. Haddad

Art Unit

1644

Page 1 of 1

**U.S. PATENT DOCUMENTS**

*	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
A	US-			
B	US-			
C	US-			
D	US-			
E	US-			
F	US-			
G	US-			
H	US-			
I	US-			
J	US-			
K	US-			
L	US-			
M	US-			

**FOREIGN PATENT DOCUMENTS**

*	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
N					
O					
P					
Q					
R					
S					
T					

**NON-PATENT DOCUMENTS**

*	Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
*	U Polman et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354(9):899-910.
*	V Munschauer et al Natalizumab significantly increases the cumulative probability of sustained improvement in physical disability. Abstract P474, World on Treatment and research in multiple sclerosis, september 17-20, 2008, montreal, Canada.
	W National Horizon Scanning Centre: New and Emerging Technology Briefing-Natalizumab for Multiple Sclerosis. July 2002, pages 1-5.
X	Tubridy et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology. 1999 Aug 11;53(3):466-72

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a))  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.